SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shasun Pharmaceuticals is currently trading at Rs. 84.30, up by 0.30 points or 0.36% from its previous closing of Rs. 84.00 on the BSE.

The scrip opened at Rs. 86.25 and has touched a high and low of Rs. 87.00 and Rs. 84.00 respectively. So far 52649 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 2 has touched a 52 week high of Rs. 91.50 on 24-Feb-2012 and a 52 week low of Rs. 38.10 on 16-Dec-2011.

Last one week high and low of the scrip stood at Rs. 89.50 and Rs. 83.55 respectively. The current market cap of the company is Rs. 408.02 crore.

The promoters holding in the company stood at 46.73% while Institutions and Non-Institutions held 16.45% and 36.83% respectively. 

Shasun Pharmaceuticals has received its board’s approval for the preferential allotment to Caduceus Mauritius Asia (CAML), a wholly owned subsidiary of OrbiMed Asia Partners. The company will allot 65,78,947 equity shares at Rs 76 per share, aggregating to Rs 50 crore.

OrbiMed is the world’s largest healthcare dedicated investment firm, with about $5 billion in assets under management.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R & D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×